Filter Releases
 
Press Releases
Date Title and Summary View
Dec 11, 2014
WALTHAM, Mass., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it presented data from a Phase 1 clinical study on estrogen receptor engagement by the investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD), in a poster presentation at the 2014 San Antonio Breast Cancer Symposium (...
Nov 24, 2014
-- Multi-center, multi-national, double-blind, placebo-controlled trial in which postmenopausal women were randomized to receive 24-weeks of treatment with either daily subcutaneous injections of placebo, the investigational drug abaloparatide 20, 40 or 80-μg, or teriparatide 20-μg. A 24-week extension also was performed in a subset of su...
Nov 17, 2014
Company selected to present at Informa's Therapeutic Area Partnerships meeting at 1:30 pm ET on Thursday, November 20 in Boston WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its investigat...
Nov 17, 2014
WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that President and CEO, Robert Ward, is scheduled to present at the Jefferies Global London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on November 20 at the Waldorf Hilton in London.About Radius Health Radius is a science-driven bioph...
Nov 10, 2014
WALTHAM, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, reported its financial results for the third quar...
Nov 3, 2014
WALTHAM, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today the appointment of Dr. Willard H. Dere, to its Board of Directors. Dr. Dere was formerly at Amgen, where he led the development program of Prolia. "We are very pleased to welcome Dr. Willard Dere to the Radius Health Board," said President and CEO...
Oct 28, 2014
WALTHAM, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its Vice President, Business Development & Strategy, Geoffrey A. Swire, will present at the BIO-Europe Conference on Wednesday, November 5, 2014 at 12:45 p.m. Central European Time at the Portalhaus Messe Frankfurt, in Frankfurt, Germany. BI...
Oct 23, 2014
WALTHAM, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today it is a sponsor of The Cancer Support Community's symposium, "The Patient Voice: The First Year of the Cancer Experience Registry," in recognition of National Breast Cancer Awareness Month. Radius is pleased to help be a sponsor of this patient-focus...
Oct 21, 2014
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2014 financial results on Tuesday, November 11, 2014. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Tuesday, November 11, 2014 to disc...
Oct 2, 2014
WALTHAM, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, announced today that it has priced its public offeri...
Oct 1, 2014
WALTHAM, Mass., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commencing an underwritte...
Sep 25, 2014
Radius Health Summarizes Recent Presentations regarding its Investigational Drug Abaloparatide at the American Society for Bone and Mineral Research and for its Investigational Drug RAD1901 at the 4th Annual Brain Metastases Research and Emerging Therapy ConferenceInvestigational Drug Abaloparatide Currently in Phase 3 Clinical Development, Top Lin...
Sep 11, 2014
CAMBRIDGE, Mass., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its President and CEO, Robert Ward, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 2:00 p.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York. ...
Sep 8, 2014
Live Panel And Conference Call Scheduled for 7:30 a.m. CDT on September 15, 2014 Data Presented During Poster Session at ASBMR 2014 WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with oste...
Aug 28, 2014
WALTHAM, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, reports that the positron emission tomography (PET) imaging from the R...
= add release to Briefcase